.jpg)
Galmed Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today that it has entered into securities purchase agreements with two institutional investors to purchase 5,600,000 of its ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase 5,600,000 ordinary shares at a combined purchase price of $1.25 per ordinary share and accompanying warrant (the "Offering"). The gross proceeds of the Offering to the Company, before placement agent fees and estimated offering expenses, are expected to be approximately $7.0 million.
Each warrant is immediately exercisable for one ordinary share at an exercise price of $1.25 per ordinary share and will expire five years from the date of issuance. The Offering is expected to close on or about July 18, 2023, subject to customary closing conditions.
Maxim Group LLC is acting as the sole placement agent in connection with the Offering.
The Offering is being conducted pursuant to the Company's registration statement on Form F-1, as amended, (File No. 333-272722) previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on July 14, 2023. A final prospectus relating to the Offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov. Copies of the final prospectus relating to this Offering, when available, may be obtained from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Galmed Pharmaceuticals Ltd.
We are a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. We have focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease. We are also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.
Source: Galmed Pharmaceuticals Ltd.
_______________________________________
FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals
Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives.
If your company has business or financial objectives check out:
Strategic advisory services provided by FC Global Strategies
Medical and Pharma Insider’s AI Connect Marketing Program
Medical and Pharma Insider is a program of FC Global Strategies.
Click here to schedule a complimentary call to discuss your company's business and financial goals.
FC Global Strategies' Contacts:
North America and Latin America
Jeffrey Friedland
+1 646 450 8909
jeffrey@fcglobalstrategies.com
The Middle East, North Africa and Eastern Europe
David Krutonog
+972 50 974 3429
david@fcglobalstrategies.com
Southeast Asia, Asia-Pacific, Australia, and New Zealand
Ross Swan
+65 9181 9472
ross@fcglobalstrategies.com
